EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

Table 5 Time to recurrence (TTR)^a and cancer-specific survival (CSS)^b of patients with intestinal-type adenocarcinomas

	Univariate survival analysis for TTR						Multivariate survival analysis for TTR			Univariate survival analysis for CSS						Multivariate survival analysis for CSS
	Number of patients	TTR, median (months)	P value, log-rank test^c	P value, Cox test^d	HR	95 % CI	P value, Cox test^b	HR	95 % CI	Number of patients	CSS, median (months)	P value, log-rank test^a	P value, Cox test^d	HR	95 % CI	P value, Cox test^b	HR	95 % CI
Age (continuous variable)	198			NS						212			0.048	1.02	1.00–1.04	NS
Patient gender
Female (reference)	71	56.6	NS	NS						78	45.6	NS	NS
Male	127	38.2								134	44.6
Site of primary tumour
Distal oesophagus/GOJ/cardia (reference)	75	28.5	NS	NS						77	34.3	NS
Corpus/antrum/pylorus	123	53.6					NS			135	47.1		NS
Histological differentiation grade
Grade I (reference)	30	NA	NS							30	NA	NS
Grade II	92	33.8		0.043	1.95	1.02–3.74	NS			98	33.8		0.020	2.22	1.13–4.36	NS
Grade III	76	53.2		NS			NS			84	44.6		0.029	2.15	1.08–4.27	NS
Postoperative T
pT1 (reference)	37	67.3	<0.0001							37	NA	<0.0001
pT2	31	NA		NS						31	NA		NS
pT3	75	56.6		NS						82	57.3		NS
pT4	55	20.5		0.002	2.59	1.44–4.67				59	25.7		0.001	2.94	1.58–5.47
Postoperative stage
I (reference)	58	NA	0.005							58	NA	<0.0001
II	80	38.2		NS			NS			80	57.3		NS			NS
III	60	22.6		0.001	2.33	1.38–3.92	0.014	2.05	1.16–3.63	60	29.0		0.002	2.36	1.37–4.08	0.023	1.99	1.10–3.61
IV	NA									14	6.90		<0.0001	14.2	6.86–29.3	<0.0001	11.4	5.34–24.4
EGFR amplification
Yes	28	21.8	0.026	0.028	1.73	1.06–2.83	NS			30	29.0	0.033	0.035	1.67	1.04–2.69	NS
No (reference)	170	56.6								182	57.3
HER2 amplification
Yes	20	44.6	NS	NS						25	22.3	NS	NS
No (reference)	178	45.6								187	45.6

ISSN: 1471-2407